Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14314018 | 1.00 | SPHK1 (0.54) | SPHK1BRD4HSD11B2HCRTR2CHRM2 | |
| SCHEMBL10272353 | 1.00 | SPHK1 (0.54) | SPHK1BRD4HSD11B2HCRTR2CHRM2 | |
| SCHEMBL9752336 | 0.90 | SPHK1 (0.51) | SPHK1BRD4HSD11B2HCRTR2CHRM2 | |
| SCHEMBL11956429 | 0.85 | SPHK1 (0.48) | SPHK1BRD4HSD11B2HCRTR2CHRM2 | |
| SCHEMBL25148798 | 0.85 | SPHK1 (0.48) | SPHK1BRD4HSD11B2HCRTR2CHRM2 | |
| SCHEMBL10223487 | 0.84 | SPHK1 (0.47) | SPHK1BRD4HSD11B2HCRTR2CHRM2 | |
| SCHEMBL9752318 | 0.82 | SPHK1 (0.45) | SPHK1BRD4HSD11B2CHRM2CHRM1 | |
| SCHEMBL8416163 | 0.81 | SPHK1 (0.48) | SPHK1BRD4HSD11B2HCRTR2CHRM2 | |
| SCHEMBL6979603 | 0.81 | SPHK1 (0.49) | SPHK1BRD4HSD11B2HCRTR2CHRM2 | |
| SCHEMBL1833725 | 0.81 | SPHK1 (0.49) | SPHK1BRD4HSD11B2HCRTR2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, KDR | SPHK1 2095/4885BRD4 4066/4885HSD11B2 502/4885 |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | SPHK1 655/4885BRD4 947/4885HSD11B2 3724/4885 |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | SPHK1 1454/4885BRD4 2439/4885HSD11B2 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.